RXULTI® (brekspiprazol) og hyperarousal – Hjernenett

Disse sidene inneholder informasjon kun beregnet på helsepersonell

Du forlater nå hjernenett.no

Foreslåtte søkeord: Avflatning , Doseringsveileder , Interaksjoner , Brekspiprazol , Oppstart to injeksjoner , Antidepressiva , Bivirkninger

RXULTI® (brekspiprazol) og hyperarousal

I denne videoen forteller Bjørn Fjelstad om betydningen av hyperarousal i det noradrenerge system, kliniske data, dosering og tolerabilitet ved RXULTI®.

RXULTI® (brexpiprazol) er et antipsykotikum i tablettform til behandling av voksne pasienter med schizofreni.1 

 

Les mer: bivirkningsrapportering

Les mer: RXULTI®  felleskatalogtekst

 

NO-REXU-0050-2023.10

NO-RXU-2300012.10.2023

  1. RXULTI® SPC 05/2023, avsnitt 4.1.

  2. Yamamoto K, Shinba T, Yoshii M. Psychiatric symptoms of noradrenergic dysfunction; A pathophysological review. Psychiatry Clin Neurosci 2014;68:1-20.

  3. Montoya A, Valladares A, Lizan L et al. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;mar 29;9:18.

  4. Citrome L, Ouyang J, Shi L et al. Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychopharmacol 2019;39:597-603.

  5. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015;164:127-135.

  6. Correll C, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015;172:870–80.

  7. Correll C, Skuban A, Hobart M, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 2016;174:82–92.

  8. Kane JM, Skuban A, Hobart M, et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res 2016;174:93–98.

  9. Fleischhacker WW, Hobart M, Ouyang J, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2016;20:11–21.

  10. RXULTI® SPC 05/2023, avsnitt 4.2.

  11. RXULTI® SPC 05/2023, avsnitt 4.8.

Dato publisert 15.09.2023